← All stocks

Neurogene Inc.

NGNE Scheduled selling only

CIK 0001404644 #2786 in the set updated 19 Sep 2026

Bought (12 mo)

$0.00

out of their own pocket, the only kind of buying there is

Sold (12 mo)

$1.13M

$1.13M on a plan · $0.00 straight out of an exercise

Sold at will

$0.00

0 of 17 sales

Net

−$1.13M

$0.00 against sales at will

By person

5 insiders · 17 transactions

78.4×

Rachel McMinn holds 78.4 times base salary in stock. $48.58M of shares against $618.80K in salary for 2025.

Salary from the company's own proxy. The shares are what Rachel McMinn last reported holding, valued at $36.13, the price Common Stock was last bought or sold at on the open market here, on 7 Jul 2026.

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

Cvijic Christine Mikail

President and CFO

—

$900.02K (12) scheduled

−$900.02K

84,040

0.4200%

$3.04M

+59.0%

Cobb Stuart

Chief Scientific Officer

—

$141.45K (3) scheduled

−$141.45K

30,497

0.1524%

$1.10M

+49.6%

McMinn Rachel

Chief Executive Officer

—

$74.00K (1) scheduled

−$74.00K

1,344,307

6.72%

$48.58M

+7.5%

Jordan Julie

Chief Medical Officer

—

$18.13K (1) scheduled

−$18.13K

12,472

0.0623%

$450.66K

—

Samsara BioCapital GP, LLC entity

10% owner

—

1,717,127

8.58%

$62.05M

+2.9%

Individual transactions

Nothing of that kind in this period.

What was left out

Form 4 filings counted 19

Amendments (4/A) skipped 3

Filings about a different issuer 0

Unreadable filings 0

Joint filings 0

Sales on a Rule 10b5-1 plan 17

Sales straight out of an exercise 0

Sales at will 0

Transactions with no price 0

Shares from compensation/vesting 69,300

History held since 21 Sep 2016